Revolutionizing Diagnostics: The Rise Of Isothermal Nucleic Acid Amplification Technology

By Author: Snehal S
Total Articles: 381
Comment this article

Introduction
Isothermal Nucleic Acid Amplification Technology (INAAT) is a molecular diagnostic technique that amplifies a specific sequence of nucleic acid in a sample using a single temperature reaction. This technology offers significant advantages over traditional PCR-based methods, such as faster amplification times, greater specificity, and reduced equipment requirements.

Global INAAT Market Overview
The Isothermal Nucleic Acid Amplification Technology/INAAT Market is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.0% during the forecast period.

Factors such as the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT are the key factors driving the market growth.

Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=839

Market Segmentations:-
Based on the product, the INAAT market is segmented into assay, kits, and reagents, and systems. Assay, kits, and reagents ...
... segment are expected to account for the largest share of the INAAT industry in 2019, Based on the type, the global market is divided into TMA, LAMP, SDA, HAD, NASBA, and other technologies.

Based on application, the INAAT market is segmented into infectious disease diagnosis, blood screening, and other applications such as cancer diagnosis, cancer research, and laboratory research, which encompass cDNA preparation, whole-genome amplification (WGA), single-nucleotide polymorphism (SNP), and mutation analysis.

Based on the end user, the market is divided into hospitals, reference laboratories, academic and research institutes, and other end users.

Regional Analysis: -
In 2019, North America is expected to account for the largest share of the global INAAT market, followed by Europe.

Recent Developments:
 In 2019, Hologic (US) launched Aptima BV and Aptima CV/TV Assays
 In 2018, Grifols (Spain) ) launched Procleix Babesia assay
 In 2018, Tecan Trading AG (Switzerland) acquired Nugen Technologies (US) which helped the company to enhance its next-generation sequencing reagents portfolio. This development helped the company to accelerate its broad genomics strategy.
 In 2016, Eiken Chemicals (Japan) signed a distribution agreement with HUMAN (Germany), for distribution of loop-mediated isothermal amplification-based tuberculosis and malaria molecular diagnostic systems in the global market (except in Japan, China, Korea, Taiwan, and Thailand).

Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=839

Top Key Players: -
The major companies in the global INAAT market include Grifols S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and Meridian Bioscience (US).

Conclusion:
In conclusion, Isothermal Nucleic Acid Amplification Technology (INAAT) is a rapidly growing field in molecular diagnostics. The advantages of INAAT over traditional PCR-based methods have contributed to its increasing adoption in the healthcare industry, especially in low-resource settings. The INAAT market is expected to continue to grow rapidly in the coming years, driven by factors such as the increasing prevalence of infectious diseases, the need for accurate and cost-effective diagnostic methods, and the rising demand for point-of-care testing.